Corcept Therapeutics Incorporated’s CORT share price has dipped by 7.02%, which has investors questioning if this is right ...

Corcept Therapeutics (CORT) closed the last trading session at $91.93, gaining 64.2% over the past four weeks, but there ...

Corcept Therapeutics Incorporated’s CORT share price has surged by 82.59%, which has investors questioning if this is right ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone. | Corcept Therapeutics’ oral antiglucocorticoid plus ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

PRGS and LOAR reported strong results. Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.

Corcept Therapeutics (NasdaqCM:CORT) saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31, ...

Corcept Therapeutics CORT over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a type of ovarian cancer without the disease getting worse in a late-stage trial ...

The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...